ARTICLE | Finance
Benlysta in Bounds
No obvious surprises for Human Genome's Benlysta in FDA guidance on lupus drugs
June 28, 2010 7:00 AM UTC
Although shares of Human Genome Sciences Inc. (NASDAQ:HGSI) fell 12% last week, FDA's final guidance for drugs to treat systemic lupus erythematosus (SLE) does not appear to create any obvious surprises: the design of the company's Phase III trials of Benlysta belimumab looks to fit within the agency's benchmarks.
The company submitted a BLA and an MAA for the human anti-BLyS (B lymphocyte stimulator protein) mAb earlier this month...